Faes Farma, S.A. Logo

Faes Farma, S.A.

FAE.MC

(4.0)
Stock Price

3,74 EUR

15.61% ROA

23.7% ROE

11x PER

Market Cap.

968.940.908,00 EUR

1.24% DER

5% Yield

20.18% NPM

Faes Farma, S.A. Stock Analysis

Faes Farma, S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Faes Farma, S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (28.78%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

4 Net Profit Growth

Over the last five years, this company's net profit has shown continuous growth, reflecting a robust financial performance and making it an attractive choice for potential investors.

5 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

6 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

7 PBV

The stock's PBV ratio (1.48x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

8 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

9 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

10 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (16), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

11 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Faes Farma, S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Faes Farma, S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Faes Farma, S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Faes Farma, S.A. Revenue
Year Revenue Growth
2003 173.343.000
2004 163.009.000 -6.34%
2005 166.449.000 2.07%
2006 185.187.000 10.12%
2007 185.940.000 0.4%
2008 194.180.000 4.24%
2009 131.406.000 -47.77%
2010 202.507.000 35.11%
2011 190.224.000 -6.46%
2012 176.109.000 -8.01%
2013 180.394.000 2.38%
2014 191.742.000 5.92%
2015 204.724.000 6.34%
2016 228.635.000 10.46%
2017 274.576.000 16.73%
2018 324.312.000 15.34%
2019 357.398.000 9.26%
2020 380.240.000 6.01%
2021 398.557.000 4.6%
2022 438.754.000 9.16%
2023 424.572.000 -3.34%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Faes Farma, S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1.871.000 100%
2009 0 0%
2010 1.303.000 100%
2011 1.357.000 3.98%
2012 1.378.000 1.52%
2013 1.377.000 -0.07%
2014 674.000 -104.3%
2015 1.989.000 66.11%
2016 2.594.000 23.32%
2017 3.177.000 18.35%
2018 2.821.000 -12.62%
2019 4.175.000 32.43%
2020 3.246.000 -28.62%
2021 3.888.000 16.51%
2022 3.716.000 -4.63%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Faes Farma, S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 38.095.000
2004 39.120.000 2.62%
2005 39.279.000 0.4%
2006 46.099.000 14.79%
2007 52.290.000 11.84%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 13.613.000 100%
2013 13.897.000 2.04%
2014 16.075.000 13.55%
2015 16.771.000 4.15%
2016 14.962.000 -12.09%
2017 19.307.000 22.5%
2018 18.450.000 -4.64%
2019 21.772.000 15.26%
2020 20.064.000 -8.51%
2021 27.931.000 28.17%
2022 28.890.000 3.32%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Faes Farma, S.A. EBITDA
Year EBITDA Growth
2003 40.461.000
2004 47.590.000 14.98%
2005 22.754.000 -109.15%
2006 22.648.000 -0.47%
2007 36.069.000 37.21%
2008 35.530.000 -1.52%
2009 19.717.000 -80.2%
2010 32.324.000 39%
2011 23.970.000 -34.85%
2012 31.193.000 23.16%
2013 36.279.000 14.02%
2014 42.562.000 14.76%
2015 47.610.000 10.6%
2016 53.630.000 11.23%
2017 56.783.000 5.55%
2018 72.607.000 21.79%
2019 91.488.000 20.64%
2020 105.613.000 13.37%
2021 114.676.000 7.9%
2022 121.502.000 5.62%
2023 138.596.000 12.33%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Faes Farma, S.A. Gross Profit
Year Gross Profit Growth
2003 112.033.000
2004 104.409.000 -7.3%
2005 166.449.000 37.27%
2006 185.187.000 10.12%
2007 115.365.000 -60.52%
2008 114.896.000 -0.41%
2009 130.564.000 12%
2010 118.565.000 -10.12%
2011 115.896.000 -2.3%
2012 113.061.000 -2.51%
2013 114.649.000 1.39%
2014 126.037.000 9.04%
2015 133.769.000 5.78%
2016 151.193.000 11.52%
2017 178.140.000 15.13%
2018 204.134.000 12.73%
2019 227.410.000 10.24%
2020 239.837.000 5.18%
2021 252.397.000 4.98%
2022 282.015.000 10.5%
2023 268.836.000 -4.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Faes Farma, S.A. Net Profit
Year Net Profit Growth
2003 19.534.000
2004 23.793.000 17.9%
2005 23.273.000 -2.23%
2006 22.772.000 -2.2%
2007 22.149.000 -2.81%
2008 19.615.000 -12.92%
2009 18.161.000 -8.01%
2010 20.002.000 9.2%
2011 14.181.000 -41.05%
2012 19.518.000 27.34%
2013 22.605.000 13.66%
2014 25.334.000 10.77%
2015 30.361.000 16.56%
2016 36.591.000 17.03%
2017 42.221.000 13.33%
2018 51.592.000 18.16%
2019 63.962.000 19.34%
2020 72.549.000 11.84%
2021 83.157.000 12.76%
2022 89.550.000 7.14%
2023 101.540.000 11.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Faes Farma, S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Faes Farma, S.A. Free Cashflow
Year Free Cashflow Growth
2006 11.307.000
2007 1.814.000 -523.32%
2008 18.093.000 89.97%
2009 6.346.000 -185.11%
2010 5.169.000 -22.77%
2011 11.915.000 56.62%
2012 21.121.000 43.59%
2013 27.479.000 23.14%
2014 28.110.000 2.24%
2015 30.766.000 8.63%
2016 37.644.000 18.27%
2017 25.079.000 -50.1%
2018 46.669.000 46.26%
2019 46.181.000 -1.06%
2020 52.766.000 12.48%
2021 20.228.000 -160.86%
2022 25.840.000 21.72%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Faes Farma, S.A. Operating Cashflow
Year Operating Cashflow Growth
2006 19.930.000
2007 13.044.000 -52.79%
2008 34.308.000 61.98%
2009 16.946.000 -102.45%
2010 15.238.000 -11.21%
2011 19.975.000 23.71%
2012 23.872.000 16.32%
2013 31.647.000 24.57%
2014 32.259.000 1.9%
2015 40.912.000 21.15%
2016 49.625.000 17.56%
2017 41.727.000 -18.93%
2018 59.336.000 29.68%
2019 67.585.000 12.21%
2020 78.489.000 13.89%
2021 79.645.000 1.45%
2022 106.788.000 25.42%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Faes Farma, S.A. Capital Expenditure
Year Capital Expenditure Growth
2006 8.623.000
2007 11.230.000 23.21%
2008 16.215.000 30.74%
2009 10.600.000 -52.97%
2010 10.069.000 -5.27%
2011 8.060.000 -24.93%
2012 2.751.000 -192.98%
2013 4.168.000 34%
2014 4.149.000 -0.46%
2015 10.146.000 59.11%
2016 11.981.000 15.32%
2017 16.648.000 28.03%
2018 12.667.000 -31.43%
2019 21.404.000 40.82%
2020 25.723.000 16.79%
2021 59.417.000 56.71%
2022 80.948.000 26.6%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Faes Farma, S.A. Equity
Year Equity Growth
2003 117.782.000
2004 130.318.000 9.62%
2005 131.603.000 0.98%
2006 139.832.000 5.88%
2007 151.038.000 7.42%
2008 156.688.000 3.61%
2009 122.926.000 -27.47%
2010 165.500.000 25.72%
2011 167.604.000 1.26%
2012 184.809.000 9.31%
2013 197.799.000 6.57%
2014 228.619.000 13.48%
2015 254.327.000 10.11%
2016 284.883.000 10.73%
2017 320.243.000 11.04%
2018 360.154.000 11.08%
2019 413.654.000 12.93%
2020 472.877.000 12.52%
2021 538.066.000 12.12%
2022 602.279.000 10.66%
2023 645.880.000 6.75%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Faes Farma, S.A. Assets
Year Assets Growth
2003 198.010.000
2004 199.287.000 0.64%
2005 216.042.000 7.76%
2006 232.434.000 7.05%
2007 272.433.000 14.68%
2008 275.015.000 0.94%
2009 235.965.000 -16.55%
2010 297.097.000 20.58%
2011 291.120.000 -2.05%
2012 286.844.000 -1.49%
2013 285.156.000 -0.59%
2014 267.233.000 -6.71%
2015 290.677.000 8.07%
2016 331.223.000 12.24%
2017 430.241.000 23.01%
2018 480.804.000 10.52%
2019 493.673.000 2.61%
2020 564.150.000 12.49%
2021 641.764.000 12.09%
2022 725.670.000 11.56%
2023 756.543.000 4.08%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Faes Farma, S.A. Liabilities
Year Liabilities Growth
2003 80.148.000
2004 68.885.000 -16.35%
2005 84.419.000 18.4%
2006 92.582.000 8.82%
2007 121.375.000 23.72%
2008 118.307.000 -2.59%
2009 113.039.000 -4.66%
2010 131.589.000 14.1%
2011 123.508.000 -6.54%
2012 102.027.000 -21.05%
2013 87.349.000 -16.8%
2014 38.607.000 -126.25%
2015 36.342.000 -6.23%
2016 46.335.000 21.57%
2017 109.466.000 57.67%
2018 120.650.000 9.27%
2019 80.019.000 -50.78%
2020 91.273.000 12.33%
2021 103.698.000 11.98%
2022 123.391.000 15.96%
2023 110.663.000 -11.5%

Faes Farma, S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.41
Net Income per Share
0.29
Price to Earning Ratio
11x
Price To Sales Ratio
2.18x
POCF Ratio
6753.6
PFCF Ratio
6636.58
Price to Book Ratio
1.53
EV to Sales
2.12
EV Over EBITDA
7.77
EV to Operating CashFlow
6456.2
EV to FreeCashFlow
6456.2
Earnings Yield
0.09
FreeCashFlow Yield
0
Market Cap
0,97 Bil.
Enterprise Value
0,94 Bil.
Graham Number
3.63
Graham NetNet
0.01

Income Statement Metrics

Net Income per Share
0.29
Income Quality
0
ROE
0.29
Return On Assets
0.15
Return On Capital Employed
0.18
Net Income per EBT
0.88
EBT Per Ebit
1.04
Ebit per Revenue
0.22
Effective Tax Rate
0.12

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.56
Operating Profit Margin
0.22
Pretax Profit Margin
0.23
Net Profit Margin
0.2

Dividends

Dividend Yield
0.05
Dividend Yield %
5
Payout Ratio
0
Dividend Per Share
0.16

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.14
Return on Tangible Assets
0.16
Days Sales Outstanding
0
Days Payables Outstanding
139.81
Days of Inventory on Hand
312.25
Receivables Turnover
0
Payables Turnover
2.61
Inventory Turnover
1.17
Capex per Share
0

Balance Sheet

Cash per Share
0,15
Book Value per Share
2,05
Tangible Book Value per Share
1.48
Shareholders Equity per Share
2.05
Interest Debt per Share
0.02
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
-0.22
Current Ratio
3.67
Tangible Asset Value
0,46 Bil.
Net Current Asset Value
0,19 Bil.
Invested Capital
0.01
Working Capital
0,22 Bil.
Intangibles to Total Assets
0.24
Average Receivables
0,00 Bil.
Average Payables
0,03 Bil.
Average Inventory
65972000
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Faes Farma, S.A. Dividends
Year Dividends Growth
2000 201
2001 181 -11.67%
2002 1 -17900%
2003 1 0%
2004 1 0%
2005 1 0%
2006 1 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Faes Farma, S.A. Profile

About Faes Farma, S.A.

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

CEO
Mr. Gonzalo Fernández de Vald
Employee
1.748
Address
Avenida Autonomía 10
Leioa, 48940

Faes Farma, S.A. Executives & BODs

Faes Farma, S.A. Executives & BODs
# Name Age
1 Mr. Mariano Ucar Angulo
Chairman of the Board of Directors
70
2 Mr. Gonzalo Fernández de Valderrama Iribarnegaray
Secretary of the Board of Directors
70

Faes Farma, S.A. Competitors

Almirall, S.A. Logo
Almirall, S.A.

ALM.MC

(2.5)
Viscofan, S.A. Logo
Viscofan, S.A.

VIS.MC

(3.0)
Vidrala, S.A. Logo
Vidrala, S.A.

VID.MC

(3.0)
Ebro Foods, S.A. Logo
Ebro Foods, S.A.

EBRO.MC

(2.2)